Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GUSB | P08236 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4210038 | 1.00 | ALOX5 (0.59) | ALOX5MAPTPOLBGUSBSMN1; SMN2 | |
| SCHEMBL9265003 | 0.87 | ALOX5 (0.50) | ALOX5NR1H2PPARA | |
| SCHEMBL6062951 | 0.87 | ALOX5 (0.50) | ALOX5NR1H2PPARA | |
| SCHEMBL9000444 | 0.85 | ALOX5 (0.48) | ALOX5MAPTPOLBGUSBSMN1; SMN2 | |
| SCHEMBL9000437 | 0.85 | ALOX5 (0.48) | ALOX5MAPTPOLBGUSBSMN1; SMN2 | |
| SCHEMBL1616183 | 0.84 | — | — | |
| SCHEMBL12855369 | 0.84 | — | — | |
| SCHEMBL13896972 | 0.84 | — | — | |
| SCHEMBL1616182 | 0.84 | — | — | |
| SCHEMBL769102 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109952652-B | Imaging element, stacked imaging element, imaging device, and electronic device | 索尼公司 | 2023-09-19 | — | — | CN | disclosed |
| US-20090227748-A1 | Process for Preparing Olff in Polymers in the Presence of Catalyst Systems Having Photochromic Groups | BASELL POLYOLEFINE GMBH (DE) | 2009-09-10 | — | — | US | disclosed |
| EP-1937700-A2 | PROCESS FOR PREPARING OLEFIN POLYMERS IN THE PRESENCE OF CATALYST SYSTEMS HAVING PHOTOCHROMIC GROUPS | Basell Polyolefine GmbH (DE) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007028536-A2 | PROCESS FOR PREPARING OLEFIN POLYMERS IN THE PRESENCE OF CATALYST SYSTEMS HAVING PHOTOCHROMIC GROUPS | BASELL POLYOLEFINE GMBH (DE) | 2007-03-15 | — | — | WO | disclosed |
| US-5434264-A | α,α-disubstituted aromatics and heteroaromatics as cognition enhancers | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-07-18 | — | — | US | disclosed |
| US-5300642-A | α, α-disubstituted aromatics and heteroaromatics as cognition enhancers | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-04-05 | — | — | US | disclosed |
| EP-0311010-B1 | Alpha,Alpha-disubstituted aromatics and heteroaromatics as cognition enhancers | DU PONT MERCK PHARMA (US) | 1994-02-02 | — | — | EP | disclosed |
| EP-0532054-A1 | Process for preparing alpha,alpha-disubstituted aromatics and heteroaromatics as cognition enhancers | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-03-17 | — | — | EP | disclosed |
| US-5173489-A | α,α-disubstituted aromatics and heteroaromatics as cognition enhancers | THE DUPONT MERCK PHARMACEUTICAL CO. (US) | 1992-12-22 | — | — | US | disclosed |
| EP-0311010-A2 | Alpha,Alpha-disubstituted aromatics and heteroaromatics as cognition enhancers | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1989-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227748-A1 | Process for Preparing Olff in Polymers in the Presence of Catalyst Systems Having Photochromic Groups | RTF1, POF1B, RTF2 | ALOX5 623/4885MAPT 2272/4885POLB 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.